title: Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
abstract: OBJECTIVE
  The JFMC33-0502 trial is a phase III clinical study designed to determine the most appropriate duration of postoperative adjuvant chemotherapy with uracil-tegafur (UFT) plus leucovorin in patients with stage IIB or III colon cancer. We report the interim results of preplanned safety analyses.
  
  
  METHODS
  Patients with stage IIB or III colon cancer who had undergone curative resection were randomly assigned to receive UFT (300 mg/m(2)) plus leucovorin (75 mg/day) for 6 months (control group, 4 weeks of treatment followed by a 1-week rest, five courses) or for 18 months (study group, 5 days of treatment followed by a 2-day rest, 15 courses). Treatment status and safety were evaluated.
  
  
  RESULTS
  A total of 1,071 patients were enrolled, and 1,063 were included in safety analyses. Treatment completion rate at 6 months was 74.0 % in the control group and 76.7 % in the study group. Treatment completion rate in the study group at 18 months was 56.0 %. The overall incidence of adverse events (AEs) was 75.3 % in the control group and 77.6 % in the study group. The incidences of grade 3 or higher AEs were low in both groups. During the first 6 months, the incidences of the subjective AEs were significantly lower in the study group.
  
  
  CONCLUSIONS
  Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy. In particular, 5 days of treatment followed by a 2-day rest was a useful treatment option from the viewpoint of toxicity even when given for longer than 6 months.
authors.affiliation: Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, 983-0824, Japan, tsuchiya@openhp.or.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Sotaro
authors.initials: S
authors.lastname: Sadahiro
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Sasaki
authors.forename: Ken
authors.initials: K
authors.lastname: Kondo
authors.forename: Kenji
authors.initials: K
authors.lastname: Katsumata
authors.forename: Genichi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kakeji
authors.forename: Hideo
authors.initials: H
authors.lastname: Baba
authors.forename: Takayuki
authors.initials: T
authors.lastname: Morita
authors.forename: Keiji
authors.initials: K
authors.lastname: Koda
authors.forename: Seiji
authors.initials: S
authors.lastname: Sato
authors.forename: Junji
authors.initials: J
authors.lastname: Matsuoka
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Usuki
authors.forename: Chikuma
authors.initials: C
authors.lastname: Hamada
authors.forename: Susumu
authors.initials: S
authors.lastname: Kodaira
authors.forename: Shigetoyo
authors.initials: S
authors.lastname: Saji
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012307:Risk Factors; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D002955:Leucovorin
references.citation: N Engl J Med. 2005 Jun 30;352(26):2696-704
references.pmid: 15987918
references.citation: Br J Cancer. 2012 Mar 27;106(7):1268-73
references.pmid: 22415232
references.citation: Langenbecks Arch Surg. 2002 Mar;386(8):575-81
references.pmid: 11914933
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8671-8
references.pmid: 16314627
references.citation: J Clin Oncol. 2009 Feb 20;27(6):872-7
references.pmid: 19124803
references.citation: Jpn J Clin Oncol. 2006 Apr;36(4):237-44
references.pmid: 16675478
references.citation: J Clin Oncol. 2006 May 1;24(13):2059-64
references.pmid: 16648506
references.citation: Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6
references.pmid: 14571738
references.citation: J Clin Oncol. 1998 Jan;16(1):295-300
references.pmid: 9440756
references.citation: N Engl J Med. 2004 Apr 22;350(17):1713-21
references.pmid: 15102997
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2896-903
references.pmid: 12885807
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: J Clin Oncol. 2006 May 20;24(15):2368-75
references.pmid: 16618946
references.citation: Int J Clin Oncol. 2012 Feb;17(1):1-29
references.pmid: 22002491